Shares of Bausch Health Companies Inc. (BHC) declined 3.81% after the company reported lower-than-expected first-quarter 2025 results.Adjusted earnings per share of 59 cents missed the Zacks Consensus Estimate of 83 cents. The earnings were also down from 60 cents in the year-ago quarter.Total revenues of $2.26 billion were up 5% year over year. The top line also missed the Zacks Consensus Estimate by 0.54%.Excluding the impact of foreign exchange of $37 million, acquisitions of $6 million and divestitures ...

Bausch Health (BHC) reported $2.26 billion in revenue for the quarter ended March 2025, representing a year-over-year increase of 4.9%. EPS of $0.59 for the same period compares to $0.59 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $2.27 billion, representing a surprise of -0.54%. The company delivered an EPS surprise of -28.92%, with the consensus EPS estimate being $0.83.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Str ...

Core Viewpoint - Bausch Health (BHC) reported quarterly earnings of $0.59 per share, missing the Zacks Consensus Estimate of $0.83 per share, indicating an earnings surprise of -28.92% [1] Financial Performance - The company posted revenues of $2.26 billion for the quarter ended March 2025, which was below the Zacks Consensus Estimate by 0.54%, compared to revenues of $2.15 billion a year ago [2] - Over the last four quarters, Bausch has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Bausch shares have declined approximately 31.6% since the beginning of the year, contrasting with the S&P 500's decline of -5.5% [3] - The current Zacks Rank for Bausch is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $1.05 on revenues of $2.46 billion, and for the current fiscal year, it is $4.26 on revenues of $9.92 billion [7] - The estimate revisions trend for Bausch is mixed, and changes in estimates for the coming quarters and current fiscal year are anticipated following the recent earnings report [6][7] Industry Context - The Medical - Generic Drugs industry, to which Bausch belongs, is currently in the top 20% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14956 Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia , Canada 98-0448205 (State or o ...

Exhibit 99.1 Investor Contact: Media Contact: Garen Sarafian Katie Savastano (877) 281-6642 (toll free) (908) 541-3785 ir@bauschhealth.com corporate.communications@bauschhealth.com BAUSCH HEALTH ANNOUNCES FIRST QUARTER 2025 RESULTS BAUSCH HEALTH EXCLUDING BAUSCH + LOMB FIRST QUARTER 2025 RESULTS LAVAL, QC, April 30, 2025 – Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its first quarter 2025 financial results and other key updates from th ...

The market expects Bausch Health (BHC) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released ...

Bausch Health (BHC) shares soared 13.3% in the last trading session to close at $5.10. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 35.7% loss over the past four weeks.Shares gained a district court in the United States granted summary judgment in favor of the company, its gastroenterology business Salix Pharmaceuticals and Teva Pharmaceuticals against Norwich which is looking to get its generic version of Xifaxan approved.Thi ...

Group 1 - One-eighth of the world's population, approximately 970 million people, suffers from some form of mental health condition [1] - In the United States, nearly 70 million people, which is one-fifth of adults, are affected by mental health issues [1] Group 2 - Ari Zoldan is the CEO of Quantum Media Group, a marketing and media agency based in New York City [1] - Zoldan is an on-air TV personality featured on networks such as FOX, CNN, and CNBC, focusing on technology, media, and business trends [1] - He serves as Chair of the Media & Development committee for The Zahn Center for Innovation at City College [1] - Zoldan has reported from various war-torn and conflicted regions, including South Sudan, Uganda, Nicaragua, Haiti, Burma, and Guinea [1] - He holds press credentials for Capitol Hill and the United Nations and is a member of the National Press Club in Washington, DC [1]

Group 1 - The marketplace channel Haggerston BioHealth offers exclusive stock tips focused on Pharma, Biotech, and Healthcare, providing access to investment bank-grade financial models and research [1][2] - The group caters to both novice and experienced biotech investors, offering insights on catalysts, buy and sell ratings, product sales forecasts, and integrated financial statements [2] - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the Haggerston BioHealth investing group and has compiled detailed reports on over 1,000 companies [2]

Chris Lau is an individual investor and economist with 30 years of experience covering life science, technology, and dividend-growth income stocks. He has degrees in Microbiology and Economics. Chris runs the investing group DIY Value Investing where he shares his top stock picks of undervalued stocks with catalysts for upside, dividend-income recommendations with quant and payment calendar tracking, high upside plays, and research requests to help you become a better do-it-yourself investor. Learn more.Top ...